CSIMarket
 
Kamada Ltd   (KMDA)
Other Ticker:  
 
 
Price: $5.8700 $0.27 4.821%
Day's High: $5.88 Week Perf: 1.38 %
Day's Low: $ 5.71 30 Day Perf: -4.4 %
Volume (M): 25 52 Wk High: $ 6.53
Volume (M$): $ 147 52 Wk Avg: $5.23
Open: $5.71 52 Wk Low: $4.08



 Market Capitalization (Millions $) 324
 Shares Outstanding (Millions) 55
 Employees 495
 Revenues (TTM) (Millions $) 143
 Net Income (TTM) (Millions $) 8
 Cash Flow (TTM) (Millions $) 34
 Capital Exp. (TTM) (Millions $) 0

Kamada Ltd
Kamada Ltd is a biopharmaceutical company that operates in the fields of plasma-derived proteins and immunoglobulins for various medical conditions. The company has over thirty years of experience in the development and commercialization of innovative therapeutics for patients with rare and chronic diseases.

Founded in 1990, Kamada Ltd is headquartered in Rehovot, Israel, and has additional offices and facilities in the United States, Germany, and the United Kingdom. The company has a global network of distributors and partners, enabling it to market its products to medical professionals worldwide.

Kamada Ltd is dedicated to developing therapeutic products to treat a variety of life-threatening conditions, including bleeding disorders, immunodeficiency diseases, pulmonary arterial hypertension, and other medical conditions that require specific proteins and enzymes for treatment. They offer a comprehensive range of products, including Alpha1- Antitrypsin, Immunoglobulin, Coagulation Factors, and other related products.

The company's flagship product, Glassia, is an FDA-approved Alpha1-Proteinase Inhibitor that is used to treat genetic emphysema, a life-threatening condition that affects the lungs. In addition, Kamada Ltd also offers a range of coagulation factors, which are essential for the effective treatment of Bleeding Disorders.

One of Kamada Ltd's significant strengths is its ability to control the entire manufacturing process, from start to finish, to ensure the highest quality and consistency of its products. The company employs a team of dedicated specialists and scientists who use state-of-the-art scientific equipment and technology to develop and manufacture its products.

In addition to its product development activities, Kamada Ltd also offers research and development services to other pharmaceutical companies. The company has a research and development team that is focused on developing innovative and effective treatments for various medical conditions. The company also operates a clinical trial division that conducts comprehensive clinical trials to test the safety and efficacy of its products.

In conclusion, Kamada Ltd is an innovative and reliable biopharmaceutical company that provides high-quality plasma-derived products and immunoglobulins to patients worldwide. The company's commitment to research and development, quality control, and customer service has enabled it to become a leader in the field of biopharmaceuticals.


   Company Address: 2 Holzman St Rehovot 7670402
   Company Phone Number: 8 9406472   Stock Exchange / Ticker: NASDAQ KMDA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Kamada Ltd

Breaking Records: Kamada Ltd Shines with Outstanding Performance in Q4 2023

Kamada Ltd, a global biopharmaceutical company, has recently announced its financial results for the three months and year ended December 31, 2023. Despite facing challenges in the past, the company seems to be making progress towards improving its profitability.
In a letter to shareholders, Kamada's Chief Executive Officer, Amir London, discussed the company's performance and outlined its plans for the future. One of the key points highlighted in the letter was the recorded net loss of $2 million during the 12 months ending in the fourth quarter of 2022. This negative return on assets (ROA) of -1.32% raises concerns about the company's profitability and its ability to generate profits from its investments.

Management Announcement

Kamada Ltd.'s Road to Recovery: Facing Financial Challenges and Outlining a Path Forward.

Published Wed, Mar 6 2024 12:05 PM UTC


In a recent letter to shareholders, Kamada Ltd., a global biopharmaceutical company based in Rehovot, Israel, and Hoboken, N.J., addressed the company's financial performance and its future outlook. Amir London, the Chief Executive Officer, discussed the challenges faced by the company and outlined its plans moving forward.
One of the key points highlighted in the l...

Contract

Kamada Unlocks $180 Million Revenue Potential Through Pivotal KEDRAB Distribution Agreement with Kedrion

Published Wed, Dec 6 2023 12:00 PM UTC



Kamada Ltd., a renowned global biopharmaceutical company specializing in rare and serious conditions, has recently signed a game-changing agreement with Kedrion, a key player in the field of specialty plasma-derived products. The collaboration aims to enhance the distribution of KEDRAB, Kamada's innovative pharmaceutical product, in the United States. With this par...






 

Kamada Ltd's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Kamada Ltd does not provide revenue guidance.

Earnings Outlook
Kamada Ltd does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com